MAPK/ERK

Scientific explanation

The RAS–RAF–MEK–ERK cascade transmits mitogenic RTK signals to programmes for proliferation and differentiation.

Cancers where relevant

Breast cancer HER2+ breast cancer Lung cancer Non-small-cell lung cancer EGFR-mutant NSCLC ALK-rearranged NSCLC KRAS-driven NSCLC ROS1-rearranged NSCLC MET-altered NSCLC RET-rearranged NSCLC BRAF-mutant NSCLC Colorectal cancer MSS colorectal cancer KRAS-mutant colorectal cancer BRAF-mutant colorectal cancer HER2-amplified colorectal cancer Pancreatic cancer Bladder cancer Acute myeloid leukemia Melanoma BRAF-driven melanoma NRAS-driven melanoma KIT-associated melanoma Thyroid cancer

Compounds that intersect this pathway

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.